Press Releases

Press Releases

Date	Title	Format
May 24, 2022	Chinook Therapeutics Announces Pricing of a $105 Million Public Offering	PDF Version
May 24, 2022	Chinook Therapeutics Announces Proposed Public Offering	PDF Version
May 20, 2022	Chinook Therapeutics Presents Data from Atrasentan Phase 2 AFFINITY IgA Nephropathy (IgAN) Patient Cohort and Evotec Collaboration at the 59th European Renal Association (ERA) Congress 2022	PDF Version
May 19, 2022	Chinook Therapeutics Presents Updated Data from BION-1301 Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) and from Atrasentan Preclinical Mechanism of Action Studies at the 59th European Renal Association (ERA) Congress 2022	PDF Version
May 12, 2022	Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	PDF Version
May 12, 2022	Chinook Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results	PDF Version
May 2, 2022	Chinook Therapeutics Announces Upcoming Data Presentations and Investor Conference Call at the 59th European Renal Association (ERA) Congress	PDF Version
April 25, 2022	Chinook Therapeutics to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference	PDF Version
April 12, 2022	Chinook Therapeutics Announces Initiation of Phase 1 Healthy Volunteer Trial of CHK-336, a First-in-Class LDHA Inhibitor to Treat Hyperoxalurias	PDF Version
April 5, 2022	Chinook Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference	PDF Version

Email Alerts

Investors